Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors

Erbilgin, Yucel; Eskazan, Ahmet Emre; Ongoren, Seniz; Ar, Muhlis Cem; Baslar, Zafer; Soysal, Teoman; Sayitoglu, Muge; Ozbek, Ugur; Ng, Ozden Hatirnaz; Salihoglu, Ayse; Elverdi, Tugrul; Firtina, Sinem; Tasar, Orcun; MERCAN, SEVCAN; Sisko, Sinem; Khodzhaev, Khusan

doi:10.1080/10428194.2018.1473573

Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors

Yazarlar (16)

Doç. Dr. Yucel Erbilgin Istanbul Üniversitesi, Türkiye

Prof. Dr. Ahmet Emre Eskazan İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye

Prof. Dr. Ozden Hatirnaz Ng Istanbul Üniversitesi, Türkiye

Prof. Dr. Ayse Salihoglu İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye

Dr. Öğr. Üyesi Tugrul Elverdi İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye

Doç. Dr. Sinem Firtina Istanbul Üniversitesi, Türkiye

Orcun Tasar
Istanbul Üniversitesi, Türkiye

Dr. Öğr. Üyesi Sevcan MERCAN Kafkas Üniversitesi, Türkiye

Sinem Sisko
Istanbul Üniversitesi, Türkiye

Khusan Khodzhaev
Istanbul Üniversitesi, Türkiye

Seniz Ongoren
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye

Prof. Dr. Muhlis Cem Ar İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye

Prof. Dr. Zafer Baslar İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye

Teoman Soysal
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye

Prof. Dr. Muge Sayitoglu Istanbul Üniversitesi, Türkiye

Öğr. Gör. Ugur Ozbek Istanbul Üniversitesi, Türkiye

Makale Türü	Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı	Leukemia and Lymphoma
Dergi ISSN	1042-8194 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler	SCI-Expanded
Makale Dili	İngilizce	Basım Tarihi	12-2018
Cilt / Sayı / Sayfa	60 / 1 / 200–207	DOI	10.1080/10428194.2018.1473573
Makale Linki	https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1473573

Özet

Tyrosine kinase inhibitor (TKI) therapy is the current treatment of choice for patients with chronic phase chronic myeloid leukemia (CML) leading to rapid and durable hematological as well as molecular responses. However, emergence of resistance to TKIs has been the major obstacle to treatment success on long term. In this regard kinase domain mutations are the most common mechanism of therapy failure. In this study, we analyzed peripheral blood samples from 17 CML patients who had developed resistance to various TKIs by using next-generation sequencing parallel to Sanger sequencing. BCR-ABL1 kinase domain mutations have been found in 59% of the cohort. Our results demonstrate that next-generation sequencing results in a higher mutational detection rate than reported with conventional sequencing methodology. Furthermore, it showed the clonal diversity more accurately.

Anahtar Kelimeler

Chronic myeloid leukemia | drug resistance | next-generation sequencing | tyrosine kinase inhibitor

Pdf İndir

BM Sürdürülebilir Kalkınma Amaçları

Atıf Sayıları
Scopus	16
Google Scholar	23

Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors

Dergi Adı	LEUKEMIA & LYMPHOMA
Yayıncı	Taylor and Francis Ltd.
Açık Erişim	Hayır
ISSN	1042-8194
E-ISSN	1029-2403
CiteScore	4,1
SJR	0,778
SNIP	0,604

Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors

Paylaş